Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jun 17;333(23):2061-2072.
doi: 10.1001/jama.2025.4390.

Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial

Affiliations
Multicenter Study

Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial

Scott R Garrison et al. JAMA. .

Abstract

Importance: Whether administration of blood pressure medications at bedtime instead of in the morning reduces cardiovascular risk is unknown, as findings from large clinical trials have not been consistent. There is also concern that bedtime antihypertensive use could induce glaucoma-related visual loss or other hypotensive/ischemic adverse effects.

Objective: To determine the effect of bedtime vs morning administration of antihypertensive medications on major cardiovascular events and death.

Design, setting, and participants: Multicenter, open-label, pragmatic randomized clinical trial with blinded end-point assessment and recruitment via 436 primary care clinicians across 5 Canadian provinces inviting their community-dwelling adult patients with hypertension taking at least 1 once-daily antihypertensive medication. Participants were recruited from March 31, 2017, to May 26, 2022, with final follow-up on December 22, 2023.

Interventions: Participants were randomized in a 1:1 ratio to using all once-daily antihypertensive medications either at bedtime (intervention group; n = 1677) or in the morning (control group; n = 1680).

Main outcomes and measures: The primary outcome was time to first occurrence of all-cause death or hospitalization/emergency department (ED) visit for stroke, acute coronary syndrome, or heart failure. All-cause unplanned hospitalizations/ED visits, and visual, cognitive, and fall- and/or fracture-related safety outcomes were also assessed.

Results: A total of 3357 adults (56.4% female; median age, 67 years; 53.7% taking monotherapy) were randomized and followed up for a median of 4.6 years in each treatment group. The composite primary outcome event occurred at a rate of 2.3 per 100 patient-years in the bedtime group and 2.4 per 100 patient-years in the morning group (adjusted hazard ratio, 0.96; 95% CI, 0.77-1.19; P = .70). Individual components of the primary outcome, all-cause hospitalizations/ED visits, and safety outcomes did not differ between groups. In particular, there was no difference in falls or fractures, new glaucoma diagnoses, or 18-month cognitive decline.

Conclusions and relevance: Among adults with hypertension in primary care, bedtime administration of antihypertensive medications was safe but did not reduce cardiovascular risk. Antihypertensive medication administration time did not affect the risks and benefits of blood pressure-lowering medication and instead should be guided by patient preferences.

Trial registration: ClinicalTrials.gov Identifier: NCT02990663.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Padwal reported being past chief executive officer of mmHg, a digital health company. Dr Hill reported receipt of grants from Boehringer Ingelheim and Medtronic to the University of Calgary and being president of the not-for-profit Canadian Neurological Sciences Federation. Dr Singer reported being paid by the University of Manitoba for academic work; receiving honoraria for advisory work by the College of Physicians and Surgeons of Manitoba (2024), Canadian Cardiovascular Society (2024), Manitoba’s Southern Chiefs Organization (2021-2023), and Canadian Association of Drugs and Technology for Health (2024); participating on teams with grant funding from the Canadian Institutes of Health Research, Research Manitoba, Public Health Agency of Canada, Bayer (administered by Research Manitoba), Children’s Hospital Research Foundation, Health Science Centre Foundation, and Pfizer; being the principal investigator on a grant funded by IBM and Calian administered by the Canadian Institute for Military and Veterans Health Research; and participating in advocacy committees for the College of Family Physicians of Canada, Canadian Cardiovascular Society, and Choosing Wisely Canada. No other disclosures were reported.

Comment on

Similar articles

Cited by

References

    1. Veerman DP, Imholz BP, Wieling W, Wesseling KH, van Montfrans GA. Circadian profile of systemic hemodynamics. Hypertension. 1995;26(1):55-59. doi: 10.1161/01.HYP.26.1.55 - DOI - PubMed
    1. Mancia G, Ferrari A, Gregorini L, et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res. 1983;53(1):96-104. doi: 10.1161/01.RES.53.1.96 - DOI - PubMed
    1. Staplin N, de la Sierra A, Ruilope LM, et al. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. Lancet. 2023;401(10393):2041-2050. doi: 10.1016/S0140-6736(23)00733-X - DOI - PubMed
    1. Clement DL, De Buyzere ML, De Bacquer DA, et al. ; Office Versus Ambulatory Pressure Study Investigators . Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348(24):2407-2415. doi: 10.1056/NEJMoa022273 - DOI - PubMed
    1. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55-61. doi: 10.1161/HYPERTENSIONAHA.107.100727 - DOI - PubMed

MeSH terms

Substances

Associated data

Grants and funding